About Actin, alpha skeletal muscle
Actin, alpha skeletal muscle (ACTA1) is a protein
from Homo sapiens identified by UniProt accession
P68133, 377 residues long.
MolForge cross-references it against 0 known binders and
880 disease associations.
Target properties
| Protein name | Actin, alpha skeletal muscle |
| UniProt accession | P68133 |
| Gene | ACTA1 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (880)
Diseases linked to this target (Open Targets).
- nemaline myopathy 3 · score 0.86
- severe congenital nemaline myopathy · score 0.67
- progressive scapulohumeroperoneal distal myopathy · score 0.65
- congenital myopathy 2b, severe infantile, autosomal recessive · score 0.62
- congenital fiber-type disproportion myopathy · score 0.60
- alpha-actinopathy · score 0.54
- nemaline myopathy · score 0.49
- neuromuscular disease · score 0.46
- dilated cardiomyopathy · score 0.45
- myopathy · score 0.44
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P68133-F1 | alphafold | PREDICTED | 95.10 | — |
Amino-acid sequence (377 residues)
MCDEDETTAL VCDNGSGLVK AGFAGDDAPR AVFPSIVGRP RHQGVMVGMG QKDSYVGDEA QSKRGILTLK YPIEHGIITN WDDMEKIWHH TFYNELRVAP EEHPTLLTEA PLNPKANREK MTQIMFETFN VPAMYVAIQA VLSLYASGRT TGIVLDSGDG VTHNVPIYEG YALPHAIMRL DLAGRDLTDY LMKILTERGY SFVTTAEREI VRDIKEKLCY VALDFENEMA TAASSSSLEK SYELPDGQVI TIGNERFRCP ETLFQPSFIG MESAGIHETT YNSIMKCDID IRKDLYANNV MSGGTTMYPG IADRMQKEIT ALAPSTMKIK IIAPPERKYS VWIGGSILAS LSTFQQMWIT KQEYDEAGPS IVHRKCF
Explore Actin, alpha skeletal muscle with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets